Literature DB >> 8152357

Determining transition probabilities: confusion and suggestions.

D K Miller1, S M Homan.   

Abstract

Confusion regarding proper use of the terms rate and risk persists in the literature. This has implications for the proper modeling of prognosis and transition between health states in decision analysis and related techniques. The issue is complicated by the plethora of terms related to rate and risk. Although the suggestion to use the terms force and probability as substitutes for rate and risk has some appeal, the change in terminology by itself is unlikely to solve all the confusion or misuse of terms. This paper clarifies the proper definitions and estimations of rates and risks and suggests critical factors for the decision analyst to remember when using, modeling, or interpreting transition rates and risks.

Mesh:

Year:  1994        PMID: 8152357     DOI: 10.1177/0272989X9401400107

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  51 in total

Review 1.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer.

Authors:  Antônio M Bós; Barbara V Howard; Shirley A A Beresford; Nicole Urban; Lesley F Tinker; Hugh Waters; Angelo J Bós; Rowan Chlebowski; Jacqueline M Ennis
Journal:  J Am Diet Assoc       Date:  2011-01

4.  Rates and probabilities in economic modelling: transformation, translation and appropriate application.

Authors:  Rachael L Fleurence; Christopher S Hollenbeak
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.

Authors:  Margarita Capel; María Mareque; Carlos José Álvarez; Leandro Lindner; Itziar Oyagüez
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

6.  Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

Authors:  S P Elliott; T J Wilt; K M Kuntz
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-06-21       Impact factor: 5.554

7.  Cost-utility analysis of nonalcoholic steatohepatitis screening.

Authors:  Eric Zhang; Claire Wartelle-Bladou; Luigi Lepanto; Jean Lachaine; Guy Cloutier; An Tang
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

8.  Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

Authors:  M Nuijten; L Meester; F Waibel; S Wait
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 9.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

10.  Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.

Authors:  Virginie Nerich; Camille Fleck; Loïc Chaigneau; Nicolas Isambert; Christophe Borg; Elsa Kalbacher; Marine Jary; Pauline Simon; Xavier Pivot; Jean-Yves Blay; Samuel Limat
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.